Karyopharm seeks $80m IPO for Phase II/III cancer studies

Karyopharm Therapeutics registered an $80m initial public offering within months of raising $67.2m in a Series B venture funding round and after the company said the private financing would allow it to complete two Phase II/III clinical trials for lead drug candidate Selinexor (KPT-330) and file for US FDA approval without having to engage a US partner.